MTOR and tuberous sclerosis: Based on these findings, the International Tuberous Sclerosis Complex Consensus Conference (ITSCCC) recommends the use of an mTOR inhibitor as first-line therapy for asymptomatic or growing AMLs larger than 3 cm [12].